Studies on different physiological and pathophysiological properties of the dopaminergic system have led to novel evidences and theories that suggest the possible targeting of such system in a variety of pathologies and disorders. Herein, we illustrate the applications and the therapeutic importance that such findings and advances might have. We hope that the content of this work will guide researches devoted to dopaminergic aspects that combine neurosciences with pharmacology.
SELECTED THERAPEUTICS AND PHARMACOLOGICAL POSSIBILITIES
Based on the biological properties and the pharmacological observations, divers emerging possibilities and applications came out and described how dopaminergic system already constitutes a target for some diseases and a potential target for other pathologies. As instance, administering dopamine D2 agonists could target D2 sensitization and attenuate relapse [44] .On the other hand, dopamine has a protective effect in the retina [5] supposing a possible therapeutic application of the dopaminergic agonists. In psychiatry, the links between both the pleasure [45, 46] and the anti-stress effect [47] on one side with the dopamine on the other side may constitute a starting point to new psychiatric drugs. DRs stimulation leads to an increased feelings of wellbeing [48] and stress reduction [49] supposing also a possible targeting of the dopaminergic system in some psychiatric and psychological diseases. It has also been reported that individuals with lack of D2 receptors have an important risk to develop eating bingeing, pathological gambling, sex addiction, ADHD, and antisocial behavior [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] and authors suggested a possible link between the heightened DA efficacy and adolescents' risk-taking and emotional lability [63] .
In addition, hyperactivity of the dopaminergic system was involved in the positive symptoms of schizophrenia [64] [65] [66] and it has been reported that cognitive deficits in schizophrenia may be aggravated by the dopaminergic impairments [67] . On the other hand, positive symptoms in schizophrenia may be controlled by the use of D2 blockers via increasing the activity of GABA systems [68] and many authors suggested that D1 agonists and D2 antagonists can increase NMDAR-and GABA-R-activated synaptic conductances and thus, be useful in the treatment of schizophrenic symptoms [2, 69] . Herein, we mention that Reward Deficiency Syndrome (RDS) treatments was proposed as a multi-approach that includes slow acting and less powerful dopamine agonists and natural dopaminergic repletion therapy in addition to exercise and an appropriate diet [70] . Importantly, D1-like receptors agonists have been proposed as an antihypertension treatment [71] .
For the neurodegenerative diseases both neurite outgrowth and an increased high-affinity DA uptake has been reported as the results of the GDNF-promoted survival and differentiation of DA neurons [72] [73] [74] [75] highlighting link between the DA and the neurite outgrowth for which many publications pointed out the dopamine D5 receptor as playing a role in it. Indeed, dopamine has the ability to promote or inhibit neurite outgrowth [76] [77] [78] therefore, a detailed description of the divers DRs remains important to clarify the role of dopamine during development and regeneration [6] . Importantly, D5 receptors that are localized in the substantia nigra-pars compacta, hypothalamus, striatum, cerebral cortex, nucleus accumbens and olfactory tubercle [79] , have been linked to neurogrowth functions. In fact, D1-like receptors (D1 and D5) likely [78] . D1-like receptors is also associated with an antiapoptotic effect in early postnatal retinas [80] and both dopamine and a D1-agonist have a protective effect of the retinal neurons via the inhibition of the glutamate-induced activation of nitric oxide synthase [81] . More important, D1/D5 receptors could represent targets to develop new pharmacological approaches to prevent synapse failure in Alzheimer's disease [82] .
Different toxicological observations could lead to possible therapeutic applications. Dopaminergic deficit leads to multiple drug-seeking behavior [5, 83] and also the fact that, in alcohol preferring rodents, gene therapy has shown that DNA-directed compensatory over-expression of the DRD2 receptors can release the alcohol craving behavior [84] and in high alcohol preferring rats, D2 receptor agonists have the ability to reduce alcohol intake [85, 86] . These facts may open new therapeutic possibilities. Furthermore, several publications made a strong link between the dopaminergic system and some drugs. Previously, reward circuit has been proposed to involve dopaminergic imbalances [84] and studies carried out with Drosophila showed a role of dopaminergic systems in the cocaine's effects [87] [88] [89] . Heightened dopamine overflow in striatal regions was associated with amphetamine repeated administration [90, 91] and, in animals, dopaminergic system role was confirmed in the methamphetamine -or cocaine-induced sensitization [10] . Importantly, morphine, METH, nicotine and other abused drugs increase the dopamine release in the NAc [9] and hyperactivity of the dopaminergic system has been involved in addiction to both alcohol [92] and cocaine [93] , and in the development of tardive dyskinesia [64] . Papers have, in addition, suggested that a dysfunction in the brain reward circuitry, especially in the dopaminergic system, causes a hypodopaminergic trait [94] and individuals with lack of D2 receptors show an important risk for multiple addictive, severe alcoholism, cocaine, heroin, marijuana and nicotine use [50-57, 59-62, 95] .
These toxicological observations need to be completed by further studies that would map the related implicated mechanisms which could eventually allow the development of a new generation of drugs that would be useful in drugs withdraw and to treat drugs abuse-related symptoms.
PERSPECTIVES AND CHALLENGES
We expect more advances in the therapeutics of the dopaminergic system especially with the development of new study methods. For instance, Drosophila that has the major neurotransmitters and pathway mechanisms that exist in mammals' neural function [96, 97] , represents a model to study the divers aspects of the dopaminergic system. The "knockout" is also a laboratory approach that allows a better understanding of the dopaminergic functions. It is possible to destroy dopaminergic neurons with 6-hydroxydopamine (6-OHDA) [9] or use genetically-derived animals lacking receptors genes [1]. For example, we mention the use of "Bio-neuter" chemicals to modify the receptors expression which will create a new condition for a better study of the receptors pharmacological properties [98] . Since DRs represent GPCRs, taking into consideration the new factors that can influence GPCRs' system functions [99] could be helpful in both the study of the dopaminergic system and the development of the related drugs. Importantly, the establishment of assays for high throughput drug screening allows the identification of a higher number of active compounds [100, 101] .
However, The lack of agents for the several DR subtypes remains an obstacle for the research [4]. However, some agonist and antagonists exist in the literature. For example, the dopamine D1 receptor (D1R) agonist SKF38393, the D2 receptor agonist quinpirole [67] , dopamine D1R antagonist SCH23390 and D2 receptor (D2R) antagonist raclopride [102] have been reported. On the other hand, in disorders linked to dopaminergic hyperactivity can be therapeutically reversed using oligodeoxynucleotides [4] which illustrates possible therapeutic and laboratory usages for such kind of compounds. Importantly, pharmacognosy has introduced DRs agonists [71] which will enrich the compounds libraries the literature already has.
In pharmacovigilance, the interactions dopaminergic system may have with both drugs and neurotransmitters is a main element that should be taken into consideration especially if we consider the neurotransmitters as a part of a neural network within which many elements are in continuous interactions [103] . The dopmainirgic system may interfere with some drugs for example individuals with low D2 receptors liked the effects of psychostimulants [104] which may link the dopaminergic expression with the drugs' effects. It has also been suggested that serotonergic and dopaminergic agonists could attenuate drug seeking behavior [44] . In addition, in some medium spiny projection neurons D1 and D2 receptors are colocalized [105] in both human and rat neurons [106] supposing an inert-influence between the two receptors subtypes. Furthermore, while, D1 receptor stimulation can increase NMDA and GABA transmission, D2-receptor activation produces the opposite effect [2, 68, 107] and dopamine release is facilitated via P2 receptor activation in the mesolimbic system [108] [109] [110] . The concept of increased DA release following GABA inactivation has also been reported [44] . Dopamine D5 receptors have also been reported in the somata, dendrites, and axons of cholinergic cells [111] . In addition, dopaminergic system plays important roles within the neuro-tumoral interactions and has effects on both cancer growth and anticancer drugs [112] . These examples illustrate the interaction that the dopaminergic system has with the other neuronal networks. In addition to the possible interactions and inter-influences the dopaminergic system may have on therapeutics, these data point the importance of rigorous studies of the related pharmacovigilance.
However, pharmacological possibilities of the dopaminergic system, which belong to the big family of the GPCRs systems, remain important and need further investigations that could be supported-due to the similarities and common properties of the GPCRs-by novel advances about other GPCRs systems and related pathways. This might lead to find out both new pharmacotherapies and novel descriptions for various pathogenic phenomena [113] . Importantly, studies of the physiological basis and biological mechanisms constitute basic points to start form the pharmacological properties and reach therapeutical implications.
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